References
- Ascioglu S, Rex JH, de Pauw B et al. (2002). Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 34:7–14.
- Brüggemann RJ, Alffenaar JW, Blijlevens NM, Billaud EM, Kosterink JG, Verweij PE, Burger DM. (2009). Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents. Clin Infect Dis 48:1441–1458.
- Eiden C, Mathieu O, Peyrière H, Hillaire-Buys D, Cociglio M. (2008) Simultaneous quantification of voriconazole and its N-oxide metabolite in human plasma by an easy and rapid isocratic LC method with UV detection. Chromatographia 67:275–280.
- Ikeda Y, Umemura K, Kondo K, Sekiguchi K, Miyoshi S, Nakashima M. (2004). Pharmacokinetics of voriconazole and cytochrome P450 2C19 genetic status. Clin Pharmacol Ther 75:587–588.
- Imhof A, Schaer DJ, Schanz U, Schwarz U. (2006). Neurological adverse events to voriconazole: evidence for therapeutic drug monitoring. Swiss Med Wkly 136:739–742.
- Matsumoto K, Ikawa K, Abematsu K, Fukunaga N, Nishida K, Fukamizu T, Shimodozono Y, Morikawa N, Takeda Y, Yamada K. (2009). Correlation between voriconazole trough plasma concentration and hepatotoxicity in patients with different CYP2C19 genotypes. Int J Antimicrob Agents 34:91–94.
- Meletiadis J, Chanock S, Walsh TJ. (2008). Defining targets for investigating the pharmacogenomics of adverse drug reactions to antifungal agents. Pharmacogenomics 9:561–584.
- Mulanovich V, Lewis RE, Raad II, Kontoyiannis DP. (2007). Random plasma concentrations of voriconazole decline over time. J Infect 55:e129–e130.
- Pascual A, Calandra T, Bolay S, Buclin T, Bille J, Marchetti O. (2008). Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis 46:201–211.
- Purkins L, Wood N, Ghahramani P, Greenhalgh K, Allen MJ, Kleinermans D. (2002). Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens. Antimicrob Agents Chemother 46:2546–2553.
- Roffey SJ, Cole S, Comby P, Gibson D, Jezequel SG, Nedderman AN, Smith DA, Walker DK, Wood N. (2003). The disposition of voriconazole in mouse, rat, rabbit, guinea pig, dog, and human. Drug Metab Dispos 31:731–741.
- Scholz I, Oberwittler H, Riedel KD, Burhenne J, Weiss J, Haefeli WE, Mikus G. (2009). Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype. Br J Clin Pharmacol 68:906–915.
- Smith J, Safdar N, Knasinski V, Simmons W, Bhavnani SM, Ambrose PG, Andes D. (2006). Voriconazole therapeutic drug monitoring. Antimicrob Agents Chemother 50:1570–1572.
- Tan K, Brayshaw N, Tomaszewski K, Troke P, Wood N. (2006). Investigation of the potential relationships between plasma voriconazole concentrations and visual adverse events or liver function test abnormalities. J Clin Pharmacol 46:235–243.
- US Food and Drug Administration (2001). Briefing document for voriconazole. Basic Pharmacokinetics of Voriconazole N-oxide US Food and Drug Administration, Washington D.C. Available in 2009 at: http://www.fda.gov/ohrms/dockets/ac/01/briefing/3792b2.htm.
- Weiss J, Ten Hoevel MM, Burhenne J, Walter-Sack I, Hoffmann MM, Rengelshausen J, Haefeli WE, Mikus G. (2009). CYP2C19 genotype is a major factor contributing to the highly variable pharmacokinetics of voriconazole. J Clin Pharmacol 49:196–204.
- Wood N, Tan K, Purkins L, Layton G, Hamlin J, Kleinermans D, Nichols D. (2003). Effect of omeprazole on the steady-state pharmacokinetics of voriconazole. Br J Clin Pharmacol 56 Suppl 1:56–61.